



ASH 2024

66th ASH Annual Meeting and Exposition

December 7–10, 2024
San Diego, US



TOP ABSTRACTS

To help navigate the exciting content presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub Steering Committee members provided their recommendations for the top presented abstracts in GvHD.

ASH 2024: Top abstracts in GvHD

December 7–10, 2024

Saturday, December 7, 2024			
Abstract	Title	Speaker	Time
97 View	JAK/Rock Inhibitor Rovaclitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease: Updated Results of Multicenter, Phase 1b/2a Trial	Yanmin Zhao	09:30
98 View	Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the Agave-201 Study	Hannah Choe	09:45
99 View	A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment	Xiaodong Mo	10:00
100 View	Safety and Efficacy of the Glucagon-like Peptide 2 (GLP-2) Analog Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease (aGvHD) in Combination with Best Available Therapy: Results from a Multicenter, Randomized, Single-Blind, Proof-of-Concept, Phase 2 Stargaze Trial	Robert Zeiser	10:15
259 View	Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical Gvhd Models	Jenny Paredes	14:00
384 View	Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC	Yu Akahoshi	17:15

Monday, December 9, 2024			
Abstract	Title	Speaker	Time
1039 View	Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT	Sameem Abedin	16:30
1042 View	Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis	Sameem Abedin	17:15
1043 View	Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)	Haris Ali	17:30
1044 View	A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation	Hengwei Wu	17:45



#ASH24

Follow us on X to keep up to date
with the latest from the congress

@GvHD_Hub



Brought to you by

